80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab

• Lei Chen,
• Diane Levitan,
• Gladys Arreaza,
• Razvan Cristescu,
• Ping Qiu,
• Bo Wei,
• John Kang,
• Miho Kibukawa,
• Maureen Maguire,
• Lixin Lang,
• Deepti Aurora-Garg

Affiliations

Lei Chen

Merck and Co., Inc., Kenilworth, NJ, USA

Diane Levitan

Merck and Co., Inc., Kenilworth, NJ, USA

Gladys Arreaza

Merck and Co., Inc., Kenilworth, NJ, USA

Razvan Cristescu

Merck and Co., Inc., Kenilworth, NJ, USA

Ping Qiu

8Merck and Co., Inc., Kenilworth, NJ, USA

Bo Wei

Merck and Co., Inc., Kenilworth, NJ, USA

John Kang

Merck and Co., Inc., Kenilworth, NJ, USA

Miho Kibukawa

Merck and Co., Inc., Kenilworth, NJ, USA

Maureen Maguire

Merck and Co., Inc., Kenilworth, NJ, USA

Lixin Lang

Merck and Co., Inc., Kenilworth, NJ, USA

Deepti Aurora-Garg

Merck and Co., Inc., Kenilworth, NJ, USA